ArticleNature communications2022

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.

Kamrine E Poels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.